Lonza to expand EDS in US
Lonza is to expand its Early Development Services (EDS) offering into North America with a new, laboratory in Cambridge, Massachusetts. Covering nearly 1,600 m2, this will begin operations in May. No details were given on the expenditure involved.
Like the company’s other EDS lab in Cambridge, UK, the new lab will offer early in silico non-GMP protein expression and in vitro immunosafety assessment services. These will mainly be delivered to the preclinical stage small- to mid-sized biotechs around the Boston area.
Lonza has also completed the previously announced expansion of its bioconjugation facility at its headquarters site in Visp, Switzerland. This includes two manufacturing suites and supporting infrastructure for both clinical and commercial supply. It also complements recent expansions at the site in mammalian capacity, microbial development, drug product and HPAPI payload-linker capacity.